Maravai (MRVI): Rasio rega marang prakiraan pendapatan

Tandha merek Maravai LifeSciences Corp (MRVI)

The estimated forward P/S reflects market expectations, where the 5.30 level captures the current state. Maravai LifeSciences (MRVI) acts as a biomedicine pioneer, creating benchmark components for gene therapy. Demand for its products is non-cyclical and crisis-resistant. Meanwhile, business success relies on the volume of laboratory investments in equipment, which necessitates close monitoring of margins.

Maravai LifeSciences Holdings - Multiplikator Forward P/S MRVI (periode 04.07.2022 - 16.11.2026)

Rincian metrik lan analitis perusahaan Maravai LifeSciences (MRVI)

Analisis komprehensif perusahaan:Maravai LifeSciences Corp (MRVI)
Sampel barang Maravai

Maravai LifeSciences dominance in mRNA synthesis, driven by CleanCap patents, ensures a steady revenue stream. This cash flow serves as the foundation for calculating the forward P/S ratio, which compares the market value of shares to projected sales volume. The indicator determines the extent of the asset's overvaluation, eliminating subjective assessments and relying on financial facts. Analyzing forward capitalization to revenue allows for the identification of inflated multiplier risks and the optimization of the portfolio.

Pesaing wigati

Multiplikator Forward P/S A (agilent.com)|Quest Corp (DGX) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|ILMN - Rasio rega marang prakiraan pendapatan|EXAS - Multiplikator Forward P/S|RVTY (Revvity) - Multiplikator forward rega marang pendapatan|Bio-Rad - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan anbio.com|Multiplikator Forward P/S Sotera Health Company|Rasio rega marang prakiraan pendapatan QuidelOrtho (QDEL)|OPK - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|caredx.com - Multiplikator forward rega marang pendapatan|Rasio rega marang pendapatan sing dikarepake FLGT (Fulgent Corp)|LAB: Multiplikator forward rega marang pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake Cytek Corp CTKB|OSUR (OraSure Technologies Inc) - Multiplikator forward rega marang pendapatan|Multiplikator forward rega marang pendapatan Exagen Inc.|Multiplikator forward rega marang pendapatan MDXH|LUCD - Prakiraan rega marang pendapatan|Rasio rega marang prakiraan pendapatan Prenetics (PRE)|Rasio rega marang prakiraan pendapatan IMDX (Insight Molecular Diagnostics Inc)|Trinity Biotech - Multiplikator forward rega marang pendapatan|prophaselabs.com - Rasio rega marang prakiraan pendapatan|AIMD - Rasio rega marang prakiraan pendapatan|Co-Diagnostics Inc (CODX) - Multiplikator forward rega marang pendapatan|HSCS: Multiplikator Forward P/S|BMRA - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator forward rega marang pendapatan CDIO|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep onconetix.gcs-web.com ONCO|Rasio rega marang prakiraan pendapatan Virax Biolabs (VRAX)|Rasio rega marang pendapatan sing dikarepake BJDX|Rasio rega marang prakiraan pendapatan Vermillion AWH|Accelerate Diagnostics Inc (AXDX) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|centogene.com - Multiplikator Forward P/S|ENZ (Enzo Biochem Inc.) - Kapitalisasi marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep FRES|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep GTG Labs (GENE)|ME (23andme.com) - Multiplikator Forward P/S|Multiplikator Forward P/S Psychemedics Inc